

EUROPEAN CANCER RESEARCH *Summit* *May 3, 2021* | PORTO, PORTUGAL

PROGRAM (GMT)

Please note that in this version of the program, the time is set as GMT (Greenwich Meridian Time), which is Portugal's time zone.

08:30-09:00 - REGISTRATION

09:00-09:30 - WELCOME AND OPENING SESSION/REMARKS

Rui Henrique, Chairman of the Board, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal

Julio E. Celis, Chair of the Science Policy Committee of the European Academy of Cancer Sciences (EACS) and Danish Cancer Society Research Centre, Denmark

Stella Kyriakides, European Commissioner for Health and Food Safety, European Union

Marta Temido, Minister for Health, Portugal

Mariya Gabriel, European Commissioner for Innovation, Research, Culture, Education & Youth, European Union

Manuel Heitor, Minister for Science, Technology and Higher Education, Portugal

09:30-09:50 - KEYNOTE SPEECHES

> Route To The Cancer Mission: A Shared View Of The Cancer Community On How To Succeed | **Anton Berns**, President of the European Academy of Cancer Sciences (EACS)

> The EU Cancer Mission | **Walter Ricciardi**, President, EU Cancer Mission Board, Brussels, Belgium

09:50-10:10 - COFFEE BREAK

10:10-12:10 - SESSION 1. INFRASTRUCTURE FOR TRANSLATIONAL RESEARCH

Chair: **Ulrik Ringborg**, Cancer Center Karolinska, Stockholm, Sweden

Presentations:

> Basic/preclinical research: Generating proof of concept clinical trials is the engine for translational cancer research | **Alexander Eggermont**, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

> The Comprehensive Cancer Centre: An essential infrastructure component | **Simon Oberst**, Cancer Research UK, Cambridge Center, Cambridge, UK

> Molecular and digital pathology is essential to develop personalized/precision cancer medicine | **Fátima Carneiro**, University of Porto, Porto, Portugal

> Immunotherapy: An expanding treatment modality | **Laurence Zitvogel**, Gustave Roussy Cancer Campus, Grand Paris, France

> Liquid biopsies: Expanding diagnostic procedures for both therapeutics and prevention | **Olli Kallioniemi**, Science for Life Laboratory, Stockholm, Sweden

> Acquisition of clinical and biological data: Implementation of computational sciences (Artificial Intelligence) | **Jan Korbel**, European Molecular Biology Laboratory, Heidelberg, Germany

> **EC Knowledge Centre on Cancer | Guy Van den Eede**, *European Commission, Brussels, Belgium*

Debate:

> **Pedro Duque**, *Minister of Science and Innovation, Spain*

> **Douglas Hanahan**, *École polytechnique fédérale de Lausanne - EPFL, Lausanne, Switzerland*

> **Stefan Fröhling**, *National Center for Tumour Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany*

> **Péter Nagy**, *National Institute of Oncology, Budapest, Hungary (tbc)*

> **Ken Mastris**, *President of European Cancer Patient Coalition (ECPC), Brussels, Belgium*

> **Alexander Roediger**, *The European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium*

> **Raquel Seruca**, *Institute for Investigation and Innovation in Health (i3S), Porto, Portugal*

12:10-12:40 - LUNCH

12:40-14:40 - SESSION 2. INFRASTRUCTURE FOR CLINICAL AND PREVENTION TRIALS

Chair: **Josep Tabernero**, *Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain*

Presentations:

> **Quality assurance of clinical trials structures: harmonisation of technical requirements to support multinational institutional collaborations in next-generation clinical trials | Denis Lacombe**, *European Organisation for Research and Treatment of Cancer, Brussels, Belgium*

> **Molecular pathology for patient stratification in multicentre clinical trials | Paolo Nuciforo**, *Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain*

> **Genomics: From discovery to bench-side genomics | Emile Voest**, *The Netherlands Cancer Institute, Amsterdam, The Netherlands*

> **Modern Imaging in Oncology | Regina Beets-Tan**, *The Netherlands Cancer Institute, Amsterdam, The Netherlands*

> **Repeated biopsies (fine needle aspiration and liquid biopsies), biobanking and clinical trials registries with clinical and biological information | Benjamin Besse**, *Institute Gustave-Roussy, Grand Paris, France*

> **Development of innovative radiotherapy trials | Vincenzo Valentini**, *Policlinico Gemelli, Rome, Italy*

> **Coordination of clinical trials activities from proof-of-concept trials to practice-changing clinical trials: added value compared to present treatments | Elena Garralda**, *Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain*

> **New concepts and opportunities in cancer prevention clinical trials | Elisabete Weiderpass**, *International Agency for Research on Cancer, Lyon, France*

> **The Molecular Tumour Board: a critical infrastructure for delivery of Precision Medicine | Júlio Oliveira**, *Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal*

Debate:

> **Bettina Ryll**, *Cancer Mission Board member, Uppsala, Sweden*

> **Susan Galbraith**, *AstraZeneca, Cambridge, UK*

> **Fátima Cardoso**, *Champalimaud Clinical Center, Lisbon, Portugal*

> **José Carlos Machado**, *Institute for Investigation and Innovation in Health (i3S), Porto, Portugal*

14:40-16:40 - SESSION 3. INFRASTRUCTURE FOR OUTCOMES RESEARCH

Chair: **Joachim Schüz**, *International Agency for Research on Cancer, Lyon, France*

Presentations:

> **Outcomes research Infrastructure to support the development of primary prevention | Joachim Schüz**, *International Agency for Research on Cancer, Lyon, France*

- > Outcomes research infrastructure to support the development of cancer screening | **Partha Basu**, *International Agency for Research on Cancer, Lyon, France*
- > Outcomes research infrastructure to support the assessment of clinical effectiveness of therapeutic innovations | **Nils Wilking**, *Karolinska Institutet, Stockholm, Sweden*
- > Infrastructure support for cancer specific Health-Related Quality of Life research | **Karen Steindorf**, *National Center for Tumour Diseases and German Cancer Research Center, Heidelberg, Germany*
- > Outcomes research infrastructure for survivorship research | **Françoise Meunier**, *Former head of the European Organisation for Research and Treatment of Cancer, Brussels, Belgium*
- > Health economics as an integrated part of the cancer research continuum for prevention and therapeutics | **Bengt Jönsson**, *Stockholm School of Economics, Stockholm, Sweden*
- > A case study: outcomes implementation and measurement in lung cancer | **Marta Soares**, *Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal*

Debate:

- > **Jose M. Martin-Moreno**, *University of Valencia, Spain*
- > **Florian Alexandru Nicula**, *Institute of Oncology, Cluj-Napoca, Romania (tbc)*
- > **Matti Aapro**, *President of the European Cancer Organization, Brussels, Belgium*
- > **Gennaro Ciliberto**, *Director of Digital Institute for Cancer Outcome Research (DIGICORE), Brussels, Belgium*

16:40-16:45 - SESSION 4. OPINION ON CANCER

Eva Kondorosi, *European Commission's Group of Chief Scientific Advisors (GCSA), Brussels, Belgium*

16:45-17:05 - SESSION 5. EU-USA CANCER RESEARCH COOPERATION

Chair: Michael Baumann, *German Cancer Research Centre (DKFZ), Heidelberg, Germany*

- > Strategic development of precision cancer medicine in the US | **Richard Schilsky**, *Past President and former Chief Medical Officer, American Society of Clinical Oncology, Alexandria, VA, USA*

17:05 -17:15 - PRESENTATION OF "PORTO DECLARATION ON CANCER RESEARCH"

Manuel Heitor, *Minister for Science, Technology and Higher Education, Portugal*

17:15-17:30 - CLOSING REMARKS

- > **António Sousa Pereira**, *Rector, University of Porto, Porto, Portugal*
- > **Rui Henrique**, *Chairman of the Board, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal*
- > **Julio E. Celis**, *Chair of the Science Policy Committee of the European Academy of Cancer Sciences (EACS) and Danish Cancer Society Research Centre, Denmark*
- > **Patrick Child**, *Deputy Director General of Research & Innovation, European Commission, Brussels, Belgium*
- > **Simona Kustec**, *Minister for Education, Science and Sport, Slovenia*
- > **Manuel Heitor**, *Minister for Science, Technology and Higher Education, Portugal*

**2021
PORTUGAL.EU**



**REPÚBLICA
PORTUGUESA**